Research
Cellular
Serious adverse events were lower in the semaglutide group (13.3%) compared to the placebo group (26.7%) (P < .001).
Semaglutide may offer a safer treatment option for this patient population.
StrongSupportsmedium confidence
Serious adverse events were lower with semaglutide (13.3% vs. 26.7%;P < .001).
Why this rating
The study is a large, double-blind, placebo-controlled trial.
Source
Moving a STEP forward in the treatment of patients with obesity and heart failure with preserved ejection fraction
Giovanna Liuzzo et al. · European Heart Journal · 2023
DOI 10.1093/eurheartj/ehad674
rct · n=529
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Patients treated with semaglutide experienced a greater improvement in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) compared to placebo, with an estimated treatment difference of 7.8 points (P < .001).Strong
- Body weight decreased by 13.3% in patients treated with semaglutide compared to a marginal decrease of -2.6% in placebo-treated patients (P < .001).Strong
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →